Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction

European Heart Journal

Volumn 26, Issue 20, 2005, Pages 2193-2199

  Milliez, Paul ^a,b   DeAngelis, Noeleen ^c   Rucker Martin, Catherine ^d   Leenhardt, Antoine ^a,b   Vicaut, Eric ^b   Robidel, Estelle ^a   Beaufils, Philippe ^b   Delcayre, Claude ^a   Hatem, Stéphane N ^a,e  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Atrial fibrillation; Atrial myocardium; Fibrosis; Heart failure; Spironolactone

Indexed keywords

ATENOLOL; LISINOPRIL; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEMODYNAMIC PARAMETERS; MALE; NONHUMAN; P WAVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ALDOSTERONE ANTAGONISTS; ANIMALS; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; FIBROSIS; HEART ATRIA; HEART FAILURE, CONGESTIVE; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, WISTAR; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 26044461618     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi478     Document Type: Article

References (41)

1. Li D, Fareh S, Leung TL, Nattel S. Promotion of atrial fibrillation by heart failure in dogs. Atrial remodeling of a different sort. Circulation 1999;100:87-95.
2. Boyden PA, Tilley LP, Albala A, Liu S-K, Fenoglio Jr JJ, Wit AL. Mechanisms for atrial arrhythmias associated with cardiomyopathy: a study of feline hearts with primary myocardial disease. Circulation 1984;69:1036-1047.
3. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, Hatem SN. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34:1577-1586.
4. Rücker-Martin C, Pecker F, Godreau D, Hatem S. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovasc Res 2002;55:38-52.
5. Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in rat. J Am Coll Cardiol 2003;42:336-344.
6. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 1999;100:87-95.
7. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, Kalman JM. Electrical remodeling of the atria in congestive heart failure. Electrophysiological and electroanatomic mapping in humans. Circulation 2003;108:1461-1468.
8. Boixel C, Gonzalez W, Louedec L, Hatem SN. Mechanism of the down regulation of the L-type calcium current in atrial myocytes of rat in heart failure. Circ Res 2001;89:607-613.
9. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-246.
10. Levy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M, Aliot E, Capucci A, Cosio F, Crijns H, Jordaens L, Hauer RN, Lombardi F, Luderitz B. Atrial fibrillation: current knowledge and recommendations for management: Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-1320.
11. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-1022.
12. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation. Very new insights into very old ideas. Annu Rev Physiol 2000;62:51-77.
13. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-2614.
14. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-461.
15. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventrciular dysfunction: insight from Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;107:2926-2931.
16. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
17. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction; effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-2701.
18. Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997;95:1910-1917.
19. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards. Subcommittee on quantification of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
20. Prunier F, Gaertner R, Louedec L, Michel JB, Mercadier JJ, Escoubet B. Doppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats. Am J Physiol Heart Circ Physiol 2002;283:346-352.
21. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988;12:426-440.
22. Goette A, Arndt M, Rocken C, Spiess A, Spiess A, Staack T, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101: 2678-2681.
23. Bold A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003;42:1785-1792.
24. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96:4002-4010.
25. Shinagawa K, Shi Y, Tardi JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dog. Circulation 2002;105:2672-2678.
26. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and independent pathways. Cardiovasc Res 2003;60:315-325.
27. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002;34:1577-1584.
28. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-2706.
29. Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149.
30. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Am J Pathol 2002;161:1773-1781.
31. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 2003;284:176-184.
32. Brilla C, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;125:563-575.
33. Spach MS, Miller WT, Dolber PC, Kootsey JM, Sommer JR, Mosher CE. The functional role of structural complexities in the propagation of depolarization in the atrium of the dog: cardiac conduction disturbances due to discontinuities of effective axial resistivity. Circ Res 1982;50:175-191.
34. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscles: evidence of electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res 1986;58:356-371.
35. Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, Hauer RN, Kirkels H, Janse MJ, de Bakker JM. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001;104:3069-3075.
36. Goette A, Juenemann G, Peters G, Klein HU, Roessner A, Huth C, Rocken C. Determinants and consequences of atrial fibrosis in patient undergoing open heart surgery. Cardiovasc Res 2002;54:390-396.
37. Gencel L, Poquet F, Gosse P, Haissaguerre M, Marcus FI, Clementy J. Correlation of signal-average P wave with electrophysiological testing for atrial vulnerability in strokes of unexplained etiology. Pacing Clin Electrophsyiol 1994;17:2118-2124.
38. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Nguyen A, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005;111:3025-3033.
39. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248.
40. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435.
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (The RALES study). N Engl J Med 1999;341:709-717.